Status:
COMPLETED
Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the Objective Response Rate of KOS-1584, as a single agent in patients with stage IIIB/IV NSCLC whose disease has progressed following initial chemotherapy.
Eligibility Criteria
Inclusion
- Histologically or cytologically proven NSCLC, Stage IIIB or Stage IV.
- Eligible patients must have received only one prior chemotherapy regime for Stage IIIB/IV NSCLC.
- Good performance status.
Exclusion
- Prior treatment with an epothilone.
- Known central nervous system (CNS) metastases.
- Any chemotherapy, radiation therapy or immunotherapy or any investigational agent (therapeutic or diagnostic) within 3 weeks prior to first study drug administration.
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00651508
Start Date
April 1 2008
End Date
October 1 2008
Last Update
May 17 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Consultants In Blood Disorders & Cancer
Louisville, Kentucky, United States, 40207